Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL26097174 | 0.86 | SLC6A2 (0.30) | CHRNA7SLC6A2SLC6A4SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL4044054 | 0.85 | CHRNB2 (0.35) | CHRNB2CHRNA4CHRNA3PKM | |
| Trifluoroacetic Acid SCHEMBL5772837 | 0.85 | CHRNB2 (0.35) | CHRNB2CHRNA4CHRNA3PKM | |
| Trifluoroacetic Acid SCHEMBL1771251 | 0.82 | SLC6A1 (0.42) | CHRNB2CHRNA4CHRNA3PKMCYP2D6 | |
| Trifluoroacetic Acid SCHEMBL2912962 | 0.80 | GABRP (0.39) | CHRNB2CHRNA4CHRNA3PKMSLC6A2 | |
| Trifluoroacetic Acid SCHEMBL435875 | 0.80 | CHRM2 (0.35) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Trifluoroacetic Acid SCHEMBL21590884 | 0.79 | SLC6A2 (0.30) | CHRNA7SLC6A2SLC6A4SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL21590655 | 0.78 | SLC6A2 (0.31) | CHRNA7SLC6A2SLC6A4SLC6A3CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL21639867 | 0.77 | SLC6A2 (0.32) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Trifluoroacetic Acid SCHEMBL21196133 | 0.77 | MAN1B1 (0.34) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132500-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2024-04-25 | — | — | US | disclosed |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-11267818-B2 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2022-03-08 | — | — | US | disclosed |
| CN-110003214-B | Substituted pyrazolo [1,5-a ] pyrimidine compounds as TRK kinase inhibitors | 阵列生物制药公司 | 2021-12-21 | — | — | CN | disclosed |
| EP-3372605-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20210002287-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC. | 2021-01-07 | — | — | US | disclosed |
| US-10774085-B2 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10758542-B2 | Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190211017-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC. | 2019-07-11 | — | — | US | disclosed |
| US-10251889-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | Array BioPharm Inc. (US) | 2019-04-09 | — | — | US | disclosed |
| WO-2010048314-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20100075944-A1 | NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3) | MATSUSHIMA TOMOHIRO | 2010-03-25 | — | — | US | disclosed |
| EP-2058302-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-05-13 | — | — | EP | disclosed |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080214815-A1 | Process for preparing phenoxypyridine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-04 | — | — | US | disclosed |
| US-7354925-B2 | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists | PFIZER INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1889836-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) | Eisai R&D Management Co., Ltd. (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-20070197500-A1 | 3-(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-N,N-dimethyl-2-(pyridin-2-ylmethyl)propanamide; opioid receptor-like 1 antagonist; reduced inhibitory activity at HERG potassium channel; analgesic; side effect reduction; neurpathic and other pain | PFIZER, INC. | 2007-08-23 | — | — | US | disclosed |
| EP-1732893-A2 | ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONIST | Pfizer Japan, Inc. (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005092858-A2 | ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONIST | PFIZER JAPAN INC. (JP) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267818-B2 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | TYMP, TYMS, P2RX7 | CHRNB2 1219/4885CHRNA4 979/4885CHRNB4 1569/4885 |
| US-20240132500-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | CHRNB2 1219/4885CHRNA4 979/4885CHRNB4 1569/4885 |
| US-20190211017-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | CHRNB2 1219/4885CHRNA4 979/4885CHRNB4 1569/4885 |
| US-10251889-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | TXK, FRK, LTK | CHRNB2 1458/4885CHRNA4 1099/4885CHRNB4 1421/4885 |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, TK1 | CHRNB2 856/4885CHRNA4 676/4885CHRNB4 1059/4885 |
| US-10774085-B2 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | TYMP, TYMS, P2RX7 | CHRNB2 1219/4885CHRNA4 979/4885CHRNB4 1569/4885 |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | HGF, MET, FLT4 | CHRNB2 4179/4885CHRNA4 3231/4885CHRNB4 3685/4885 |
| US-20100075944-A1 | NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3) | HGF, MET, HDGF | CHRNB2 4131/4885CHRNA4 3143/4885CHRNB4 3657/4885 |
| US-20070197500-A1 | 3-(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-N,N-dimethyl-2-(pyridin-2-ylmethyl)propanamide; opioid receptor-like 1 antagonist; reduced inhibitory activity at HERG potassium channel; analgesic; side effect reduction; neurpathic and other pain | OPRL1, OPRD1, OPRK1 | CHRNB2 94/4885CHRNA4 102/4885CHRNB4 171/4885 |
| US-20080214815-A1 | Process for preparing phenoxypyridine derivatives | FIP1L1, SKP1, TET2 | CHRNB2 3414/4885CHRNA4 2900/4885CHRNB4 3427/4885 |
| US-20210002287-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | CHRNB2 1219/4885CHRNA4 979/4885CHRNB4 1569/4885 |
| US-10758542-B2 | Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors | LTK, TXK, FRK | CHRNB2 1581/4885CHRNA4 1172/4885CHRNB4 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.